Efficacy and Safety of Rituximab Versus Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder: A Dual-Center, Real-World Cohort Study - PubMed
5 hours ago
- #inebilizumab
- #neuromyelitis optica spectrum disorder
- #rituximab
- Comparative study of rituximab and inebilizumab in AQP4-IgG seropositive NMOSD patients.
- Retrospective analysis of 276 patients (211 rituximab, 65 inebilizumab) from two Chinese hospitals.
- Propensity score matching resulted in 61 balanced pairs for analysis.
- Comparable efficacy in time to first relapse and clinical outcomes between both treatments.
- Inebilizumab showed greater reduction in serum IgG levels at 6 months.
- Rituximab associated with higher incidence of adverse events, mainly infusion-related reactions.
- Safety profiles differed, with rituximab having more infusion-related issues.